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The APRIS (Aortic Plaque and Risk of Ischemic Stroke) Study
Marco R. Di Tullio, MD,* Shunichi Homma, MD, FACC,* Zhezhen Jin, PHD,† Ralph L. Sacco, MD‡
New York, New York; and Miami, Florida
Objectives Our goal was to assess the effect of hypercoagulability on the risk of stroke in patients with aortic plaques.
Background Atherosclerotic plaques in the aortic arch are a risk factor for ischemic stroke. Their relationship with blood hy-
percoagulability, which might enhance their embolic potential and affect treatment and prevention, is not
known.
Methods We performed transesophageal echocardiography in 255 patients with first acute ischemic stroke and in 209
control subjects matched by age, gender, and race/ethnicity. The association between arch plaques and hyper-
coagulability, and its effect on the stroke risk, was assessed with a case-control design. Stroke patients were
then followed prospectively to assess recurrent stroke and death.
Results Large (4 mm) arch plaques were associated with increased stroke risk (adjusted odds ratio [OR]: 2.4, 95%
confidence interval [CI]: 1.3 to 4.6), especially when ulcerations or superimposed thrombus were present (ad-
justed OR: 3.3, 95% CI: 1.4 to 8.2). Prothrombin fragment F 1.2, an indicator of thrombin generation, was asso-
ciated with large plaques in stroke patients (p  0.02), but not in control subjects. Over a mean follow-up of
55.1  37.2 months, stroke patients with large plaques and F 1.2 over the median value had a significantly
higher risk of recurrent stroke and death than those with large plaques but lower F 1.2 levels (230 events per
1,000 person-years vs. 85 events per 1,000 person-years; p  0.05).
Conclusions In patients presenting with acute ischemic stroke, large aortic plaques are associated with blood hypercoagula-
bility, suggesting a role for coagulation activation in the stroke mechanism. Coexistence of large aortic plaques
and blood hypercoagulability is associated with an increased risk of recurrent stroke and death. (J Am Coll
Cardiol 2008;52:855–61) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.062b
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she presence of large plaques in the proximal segment of
he aorta has been shown to be associated with an increased
isk of ischemic stroke. The association between aortic
laques and stroke, first discovered in pathology studies (1),
as been subsequently confirmed in vivo by case-control
See page 862
2–4) and prospective studies (5–7) using transesophageal
chocardiography (TEE). A relationship between plaque
hickness and stroke risk has been identified, with a cutoff of
mm widely acknowledged as clinically relevant for risk
tratification (2,6,8). Morphologic features of the plaque,
uch as presence of ulcerations or mobile components, have
rom the Departments of *Medicine and †Biostatistics, Columbia University Medical
enter, New York, New York; and the ‡Departments of Neurology, Epidemiology,
nd Human Genetics, University of Miami, Miami, Florida. The study was supported
y R01 NS36286 from the National Institute of Neurological Disorders and Stroke
NINDS). Dr. Di Tullio was the recipient of an NINDS Mid-Career Award in
atient-Oriented Research (K24 NS02241).p
Manuscript received January 15, 2008; revised manuscript received March 14,
008, accepted April 16, 2008.een identified that also contribute to the embolic risk
4,9–11).
Despite these findings, the best preventive approach to
ecrease the cerebral embolic risk of aortic plaques has
ot been identified. While there is general agreement
hat plaques with mobile components, which are often
roven to be thrombi at pathology, may require systemic
nticoagulation (8,12,13), there is no consensus on which
reatment should be used in case of large but nonmobile
laques. It has been hypothesized that superimposed
hrombotic material could at times contribute to the
laque thickness that is commonly measured by TEE (2),
nd that such a thrombotic component could enhance the
laque’s embolic potential. However, the relationship
etween aortic plaques and hypercoagulability, which
ould conceivably predispose to thrombus formation on
plaque, has not been studied. A positive association
etween plaque presence/thickness and hypercoagulabil-
ty could provide insights on stroke mechanism and
otential for preventive measures. The aim of the present
tudy was, therefore, to assess the relationship between
roximal aortic plaques presence/thickness and hyperco-
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Arch Plaques, Hypercoagulability, and Stroke September 2, 2008:855–61agulability, and to assess the
potential impact on the risk of
ischemic stroke and death.
Methods
As part of the National Institute
of Neurological Disorders and
Stroke-funded APRIS (Aortic
Plaques and Risk of Ischemic
troke) study, 255 patients over the age of 55 years with
cute ischemic stroke and 209 stroke-free control subjects
ere enrolled in the study between 1997 and 2002. Stroke
atients were consecutive patients residing in northern
anhattan, admitted to Columbia University Medical
enter with a first acute ischemic stroke, defined according
o TOAST (Trial of Org 10172 in Acute Stroke Treat-
ent) criteria (14). Control subjects were selected from the
articipants of the NOMAS (Northern Manhattan Study)
rial, and matched to cases by age (within 5 years), gender,
nd race/ethnicity. Informed consent was obtained from
ases and controls, or their health proxies when necessary.
he study was approved by the Institutional Review Board
f Columbia University Medical Center.
Hypertension was defined as a systolic blood pressure
ecording 140 mm Hg or a diastolic blood pressure
ecording 90 mm Hg based on the mean of 2 readings, a
atient’s self-report of a history of hypertension, or antihy-
ertensive medication use. Diabetes mellitus was defined by
patient’s self-report of such a history, insulin use, oral
ypoglycemic use, or a fasting glucose 126 mg/dl. Hyper-
holesterolemia was defined as total serum cholesterol240
g/dl, a patient’s self-report of hypercholesterolemia, or the
resence of lipid-lowering treatment. Smoking was defined
y current use of tobacco. The presence of atrial fibrillation
AF) was documented based on the results of a current or
ast electrocardiogram. Coronary artery disease was de-
ned as history of myocardial infarction, coronary artery
ypass grafting or percutaneous coronary intervention,
ypical angina, and use of anti-ischemic medications.
arotid duplex Doppler examination to assess for steno-
is was performed in 216 stroke patients (84.7%) and in
68 control subjects (80%).
ssessment of coagulation parameters. Since January 1,
998, fibrinogen, lupus anticoagulant, and prothrombin
ragment F 1.2 levels were measured upon presentation in
troke patients and at enrollment in control subjects.
atients in whom coagulation parameters could not be
btained at admission or who were on systemic antico-
gulation at the time of the blood drawing were not
onsidered in the analyses involving coagulation. There-
ore, all coagulation parameters were available for analysis
n 134 stroke patients and in 142 control subjects.
etection of aortic plaques. Transesophageal echocardi-
graphy was performed in stroke patients within 3 days of
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
OR  odds ratio
TEE  transesophageal
echocardiographytroke onset and in control subjects upon enrollment.ransesophageal echocardiographic examination of the
orta was performed in a systematic fashion as previously
escribed (15) using a multiplane transducer. The aortic
rch was defined as the portion of aorta comprised between
he curve at the end of the ascending portion and the takeoff
f the left subclavian artery. A plaque was defined as a
iscrete protrusion of the intimal surface of the vessel at
east 2 mm in thickness, different in appearance and
chogenicity from the adjacent intact intimal surface. The
resence and location of any plaque was recorded. In cases
f multiple plaques, the most advanced lesion was consid-
red. Plaque thickness was measured as a continuous vari-
ble. Plaques were classified as small (4 mm) or large (4
m). The presence of ulcerations or mobile components
Fig. 1) was also recorded. An ulceration was defined as a
iscrete indentation of the luminal surface of the plaque
ith base width and maximum depth of at least 2 mm each.
laques with ulceration and/or mobile components were
efined as complex plaques, according to a previously
ublished definition (4). Interpretation of the echocardio-
raphic studies was performed by a single experienced
chocardiographer (M.D.T.), blinded to case-control status.
ollow-up and outcome evaluation. All subjects were
ollowed annually by telephone. Any vascular event or
cknowledgment of neurological or cardiac symptoms dur-
ng the standardized interview triggered an in-person as-
essment. All subjects who screened positive for possible
troke were assessed in person by a neurologist. In addition,
ctive hospital surveillance of admission and discharge
nternational Classification of Diseases-9th Revision codes
as performed. Stroke was defined by the first symptomatic
ccurrence of any type of stroke as defined by TOAST
riteria (14). Diagnosis of ischemic stroke was determined
Figure 1 Example of Large,
Complex Plaque in the Aortic Arch
An ulceration and 2 faintly echogenic
superimposed thrombi are visualized (arrow).
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September 2, 2008:855–61 Arch Plaques, Hypercoagulability, and Strokey 2 neurologists independently, and the NOMAS principal
nvestigator (R.L.S.) adjudicated any disagreements. Isch-
mic stroke, fatal and nonfatal, and death were used as the
rimary outcomes of the study.
tatistical analysis. Data are presented as mean values 
SD for continuous variables and as proportions for
ategorical variables. For the case-control component of
he study, the frequency of aortic plaques was compared
n stroke patients and control subjects. Differences be-
ween proportions were assessed by the chi-square test,
eplaced by the Fisher exact test when the expected cell
ount was 5. Differences between mean values were
ssessed by the unpaired Student t test. Unadjusted odds
atios (ORs) for the association between the various
efinitions of aortic plaque and ischemic stroke were
alculated.
Multivariate logistic regression analysis was used to
est the independent association between aortic plaques
independent variable) and ischemic stroke (dependent
ariable) after entering age, gender, and stroke risk
actors as potential confounding factors in the model.
ariables significantly associated with ischemic stroke at
nivariate analysis (arterial hypertension, diabetes melli-
us, hypercholesterolemia, AF, carotid stenosis 60%)
ere entered as independent variables in the model, along
ith pertinent demographics (age, gender). The effect of
laque morphology was assessed using indicator vari-
bles, which defined plaque thickness and complexity as a
eries of binary terms. To test the effect of hypercoagu-
ability on the results, coagulation parameters were en-
ered as independent variables in the multivariate models.
nteraction terms were created to assess the combined
ffect of plaque thickness and coagulation abnormalities
n stroke risk. Adjusted ORs and 95% confidence inter-
als (CIs) were calculated from the beta coefficients and
he standard errors. The relationship between aortic
laque presence/thickness and coagulation parameters in
troke patients and control subjects was examined by the
nalysis of variance approach and F-test.
For the prospective component of the study, event rates
stroke and death) were calculated in stroke patients and in
ontrol subjects, and again in subjects with no/small plaques
r with large plaques. In stroke patients with large plaques,
nalyses were then stratified by prothrombin fragment F 1.2
evels (below or above the 50th percentile of the distribu-
ion). Kaplan-Meier event-free curves were constructed in
atients with different F 1.2 levels. The difference between
roups was evaluated by means of the log-rank test. SAS
tatistical package (version 9.1.3, SAS Institute, Cary,
orth Carolina) was used in the analyses. A 2-tailed p value
f 0.05 was considered significant for all analyses.
esults
ase-control study. The study population was comprised
f 255 patients with first-ever ischemic stroke and 209 Vtroke-free control subjects matched to patients by age,
ender, and race/ethnicity. Demographics and cardiovascu-
ar risk factors in stroke patients and in control subjects are
hown in Table 1. Stroke patients were significantly older
han control subjects, and had a significantly higher preva-
ence of hypertension and diabetes. History of AF and
arotid stenosis 60% was also more frequent in stroke
atients than in control subjects.
Large (4 mm) and complex (i.e., ulcerated or mobile)
laques in the aortic arch were more frequent in stroke
atients than in control subjects (Table 1). Ulceration or
obile components were almost exclusively seen in large
laques, with only 1 occurrence among small plaques.
mong coagulation parameters, fibrinogen and prothrom-
in fragment F 1.2 levels were also significantly higher in
troke patients (Table 1).
Table 2 illustrates the relationship between plaque thick-
ess/morphology and ischemic stroke. Plaques 4 mm
hick were associated with stroke in both univariate analysis
nd after adjustment for demographics and other stroke risk
actors. The presence of plaque ulceration or mobile com-
onents further enhanced the strength of the association of
laques with stroke.
Table 3 summarizes the relationship between plaque
resence/thickness and coagulation parameters. In stroke
atients, an increase in F 1.2 levels was observed with
ncreasing plaque thickness (p  0.07). In particular, a
ignificant elevation in F 1.2 levels was observed in patients
ith large plaque compared with patients with no plaque (p
.02). A similar trend, but no statistical significance, was
emographics, Risk Factors, Aortic Plaques, andoagulation Parameters in Stroke Patients andntrol Subjects
Table 1
Demographics, Risk Factors, Aortic Plaques, and
Coagulation Parameters in Stroke Patients and
Control Subjects
Stroke
Patients
(n  255)
Control
Subjects
(n  209) p Value
Age, yrs (SD) 70.9 (9.0) 67.0 (8.6) 0.001
Male subjects 133 (52.2) 116 (55.5) 0.47
Hypertension 226 (90.0) 145 (69.4) 0.001
Diabetes mellitus 106 (42.4) 48 (23.0) 0.001
Hypercholesterolemia 100 (40.3) 102 (48.8) 0.07
Cigarette smoking 45 (18.4) 33 (16.1) 0.51
Atrial fibrillation 29 (11.6) 11 (5.3) 0.02
Coronary artery disease 69 (27.5) 45 (21.5) 0.14
Carotid stenosis 60% 24 (11.1) 1 (0.6) 0.001
Aortic plaques
No plaque 58 (22.8) 79 (37.8) 0.001
4 mm 72 (28.4) 80 (38.1) 0.02
4 mm 124 (48.8) 50 (23.8) 0.001
Ulcerated 53 (20.8) 13 (6.2) 0.001
Mobile 4 (1.6) 1 (0.5) 0.26
Coagulation parameters
Fibrinogen, mg/ml 381.7 122.7 280.3 67.3 0.001
Lupus anticoagulant, s 39.1 11.9 40.0 10.1 0.50
F 1.2, ng/ml 1.82 1.50 1.50 1.15 0.04alues are given as n (%) unless otherwise indicated.
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Arch Plaques, Hypercoagulability, and Stroke September 2, 2008:855–61bserved for fibrinogen, whereas no relationship with plaque
hickness was observed for lupus anticoagulant. Since AF
an cause both blood stagnation and activation of coagula-
ion, the same analysis was performed after exclusion of
ubjects with history of AF. This subanalysis showed similar
esults, with a significant elevation in F 1.2 levels in stroke
atients with large plaques compared with patients with no
laque (from 1.23  0.42 ng/ml to 2.01  1.61 ng/ml; p 
.02), and also an elevation in fibrinogen levels (from 331.9
96.9 mg/ml to 398.5  115.4 mg/ml; p  0.004).
In multivariate logistic analysis adjusted for other stroke
isk factors, there was a trend toward a significant effect of
he interaction between large plaque and F 1.2 levels (as
ontinuous variable) on the risk of stroke (adjusted OR:
.61, 95% CI: 0.93 to 2.79). No trends toward interactions
ere observed between plaque thickness and the other
oagulation parameters. No significant relationship between
laque presence/thickness and any of the coagulation pa-
ameters was observed in control subjects.
Table 4 illustrates the combined effect of plaque thick-
ess/complexity and F 1.2 levels (below or above the median
alue) on the stroke risk. The effect of large plaques was
nhanced by the associated elevation of F 1.2.
ssociation Between Plaqueharacteristics and Risk of Ischemic Stroke
Table 2 Association Between PlaqueCharacteristics and Risk of Ischemic Stroke
Unadjusted OR
(95% CI)
Adjusted OR*
(95% CI)
Plaque thickness
No plaque Reference Reference
4 mm 1.2 (0.8–2.0) 1.1 (0.6–2.1)
4 mm 3.4 (2.1–5.4) 2.4 (1.3–4.6)
Plaque complexity
No ulceration and no mobility Reference Reference
Ulceration and/or mobility 3.7 (2.0–6.9) 2.3 (1.1–4.9)
Plaque thickness and complexity
No plaque Reference Reference
4 mm 1.2 (0.8–2.0) 1.1 (0.6–2.1)
4 mm, noncomplex 2.6 (1.5–4.3) 2.1 (1.0–4.1)
4 mm, complex 5.6 (2.8–11.1) 3.3 (1.4–8.2)
Adjusted for age, gender, diabetes, hypertension, hypercholesterolemia, cigarette smoking, atrial
brillation, coronary artery disease, and carotid stenosis 60%.
CI  confidence interval; OR  odds ratio.
Relationship Between Aortic Plaque Presence/TCoagulation Parameters in Stroke Pati nts and
Table 3 Relationship Between Aortic PlaqueCoagulation Parameters in Stroke P
No Plaque
Stroke patients
Prothrombin F 1.2, ng/ml 1.32 0.73
Fibrinogen, mg/ml 359.9 132.2
Lupus anticoagulant, s 41.1 17.4
Control subjects
Prothrombin F 1.2, ng/ml 1.48 1.13
Fibrinogen, mg/ml 277.8 65.3
Lupus anticoagulant, s 40.9 12.3*p  0.08 plaque 4 mm versus no plaque; †p  0.02 plaque 4 mm versollow-up results. Study subjects were followed-up for
troke or death for an average 55.1  37.2 months.
ollow-up information was available in 219 stroke patients
86%) and in all 209 control subjects. A total of 89 events
ccurred, 64 in stroke patients (29.2%) and 25 in control
ubjects (12.0%; p  0.001) (Table 5). Incidence rates of
troke or death were 133 events per 1,000 person-years in
troke patients and 17 events per 1,000 person-years in
ontrol subjects (p  0.001).
In subjects who had all necessary data, we correlated the
vent incidence rates with the presence and thickness of
ortic plaque and with F 1.2 levels. In stroke patients, large
laques were associated with increased event rates in sub-
ects with F 1.2 levels above the median value compared
ith those seen in subjects with F 1.2 levels below the
edian value (230 events per 1,000 person-years vs. 85
vents per 1,000 person-years; p  0.05). In patients with
o or small arch plaques, no significant difference was
bserved between subjects with F 1.2 levels above or below
he median value (174 events per 1,000 person-years vs. 131
vents per 1,000 person-years; p  0.58). No significant
ifferences were observed for these comparisons in control
ubjects.
Figure 2 illustrates the Kaplan-Meier event-free survival
robability in stroke patients according to initial plaque
hickness and F 1.2 levels. Subjects with large aortic plaques
nd F 1.2 levels above the median value had significantly
orse outcome than those with large plaques but lower F
.2 levels (p  0.046).
iscussion
o our knowledge, this is the first study to report on the
mpact of the activation of coagulation parameters on the
isk of stroke in patients with aortic arch plaques. In our
tudy, patients presenting with acute strokes and large aortic
rch plaques showed an elevation in F 1.2 levels that
aralleled the plaque thickness, and was not observed in
troke-free control subjects of similar age and with similar
laque thickness. Stroke patients with large plaques and F
.2 elevation had a significantly worse risk of recurrent
troke or death than those with large plaques but lower F 1.2
evels. These combined observations suggest that hyperco-
ness andntrol Subjects
sence/Thickness and
ts and in Control Subjects
laque <4 mm Plaque >4 mm p Value
1.81 1.38* 2.06 1.75† 0.07
70.5 118.5 397.5 119.6 0.21
39.5 10.5 38.0 9.3 0.39
1.55 1.24 1.44 1.03 0.90
80.4 70.1 284.3 68.1 0.90
40.1 8.0 38.1 8.8 0.43hickin Co
Pre
atien
P
3
2us no plaque.
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September 2, 2008:855–61 Arch Plaques, Hypercoagulability, and Strokegulability may contribute to the increase in stroke risk
ssociated with large aortic plaques.
ortic plaques, hypercoagulability, and ischemic
troke. In the present study, large aortic arch plaques were
ssociated with a 2.4-fold increase in the risk of ischemic
troke after adjustment for other stroke risk factors, and
ith a 3.3-fold increase in risk when ulcerations or mobile
omponents were present on the plaque surface. This
nding is consistent with previous data in the literature
ublished by us and others (2–9,11). The potential for
erebral embolization of large and complex plaque has also
een demonstrated by detecting the actual delivery of
icroemboli to the brain with transcranial Doppler moni-
oring (16). The novel aspect of our study is the association
etween plaque thickness and hypercoagulability, and their
ombined effect on the stroke risk. The embolic potential of
n aortic plaque is related to its lipid content and/or to the
resence of superimposed thrombus. The presence of
hrombus, visible in most cases on TEE as a mobile, faintly
chogenic component, has occasionally been confirmed at
urgery (17–19). In an autopsy study (20), superimposed
hrombus was detected on 17 of 120 plaques (14%). More-
ver, thromboembolism appears to be much more frequent
han atheroembolism in patients with severe aortic arch
laques, with a frequency reported to be as high as 33% at
year (5) compared with only 0.7% for atheroembolism
13). It is, therefore, conceivable that the coexistence of a
Combined Effect of Plaque Thickness/ComplexiProthrombin Fragment F 1.2 Levels on the Risk
Table 4 Combined Effect of Plaque ThicknesProthrombin Fragment F 1.2 Levels
No plaque, F 1.2  median (n  85)
Plaque 4 mm, F 1.2  median (n  43)
Plaque 4 mm, F 1.2  median (n  49)
Plaque 4 mm, F 1.2  median (n  55)
Plaque 4 mm, F 1.2  median (n  44)
Ulcerated/mobile, F 1.2  median (n  18)
Ulcerated/mobile, F 1.2  median (n  22)
*Adjusted for age, gender, diabetes, hypertension, hypercholesterolem
stenosis 60%.
Abbreviations as in Table 2.
ncidence of Nonfatal Stroke and Death (Dividedy Cause) in Stroke Patients and in Control Subjects
Table 5 Incidence of Nonfatal Stroke and Death (Dividedby Cause) in Stroke Patients and in Control Subjects
Stroke Patients
(n  219)*
Control Subjects
(n  209) p Value
Recurrent stroke (nonfatal) 19 (8.7) 0 (0) 0.001
Death 45 (20.6) 25 (12.0) 0.009
Vascular cause 19 (8.7) 10 (4.8) 0.11
Stroke 8 (3.7) 2 (1.0) 0.07
Myocardial infarction 2 (0.9) 1 (0.5) 0.59
Heart failure 2 (0.9) 1 (0.5) 0.59
Other 7 (3.2) 6 (2.9) 0.85
Nonvascular cause 17 (7.8) 12 (5.7) 0.41
Unknown cause 9 (4.1) 3 (1.4) 0.10alues are given as n (%). *Available for follow-up (from a total of 255).ypercoagulable state in a patient with aortic arch plaque
ay increase the likelihood of superimposed thrombus
ormation and further enhance the embolic potential of the
laque. In a recently published study (21), plaque progres-
ion over time was associated with increased risk of recur-
ent stroke and was predicted by the levels of homocysteine,
hose procoagulant effects are well known (22). Among
oagulation parameters, lupus anticoagulant was chosen in
ur study because of preliminary data on its possible
ssociation with aortic plaque thickness (23). Fibrinogen, a
oagulation factor, has also been shown to be independently
ssociated with thoracic aortic atherosclerosis (24). Pro-
hrombin fragment F 1.2 is considered the best indicator of
hrombin generation (25). Fragment F 1.2 is the byproduct
f the conversion of prothrombin to thrombin, which is the
nal pathway of both the intrinsic and extrinsic coagulation
echanisms. Therefore, fragment F 1.2 conceivably repre-
ents a good indicator of the net result of all procoagulant
nd anticoagulant influences in the body. In our study,
brinogen levels were significantly higher in stroke patients
han in control subjects, not surprisingly for an acute phase
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Arch Plaques, Hypercoagulability, and Stroke September 2, 2008:855–61eactant. Fragment F 1.2 levels were also significantly higher
n stroke patients, also as reported before (26,27). However,
 significant increase in F 1.2 levels with increasing aortic
laque thickness was observed in stroke patients, but not in
ontrol subjects. A similar trend was also observed for
laque thickness and fibrinogen levels. This observation is
ompatible with the hypothesis that the embolic potential of
 plaque is enhanced in the presence of an activation of the
oagulation process, and that such activation during an
cute disease is proportional to the severity of the plaque.
oreover, a trend toward an interaction of plaque thickness
nd F 1.2 levels on the stroke risk was observed, suggesting
hat the combined effect of these 2 conditions on the stroke
isk may be greater than that of either condition alone. No
elationship between plaque thickness and F 1.2 or fibrin-
gen levels was observed in control subjects, suggesting that
laques, even of large size, which are incidentally detected in
therwise healthy individuals, do not carry the same high
mbolic potential as those found in stroke patients, possibly
ecause of the absence of a coexisting activation of the
oagulation process.
These observations of the case-control study were cor-
oborated and enhanced in the follow-up component of our
tudy. Plaques 4 mm in thickness were associated with a
ignificantly increased incidence of recurrent stroke and
eath, but only in the subgroup with initial F 1.2 levels
bove the median value (Fig. 2). This finding further
einforces the concept that the combination of plaque
hickness and coagulation activation, rather than plaque
hickness alone, may be associated with worse outcomes,
nd that the reported association between aortic plaques and
ncreased stroke risk may have been partly mediated through
ctivation of the coagulation process.
omparison with previous studies and therapeutic
mplications. To our knowledge, no previous studies have
xamined the effect of hypercoagulability on the risk of
schemic stroke in patients with aortic plaques. As a conse-
uence, the use of antithrombotic treatment in stroke
atients with aortic plaques has largely been empirical, and
o specific recommendations to prevent recurrent stroke are
ontained in the current American Heart Association/
merican Stroke Association guidelines (28), except for the
eneral recommendations for lipid-lowering treatment that
re applicable to all patients with evidence of atherosclerosis.
hen a mobile thrombus is visualized on the plaque,
ystemic anticoagulation is usually initiated to prevent
ecurrent stroke, although data on its efficacy have been
btained in small, nonrandomized studies (12) or in patients
ith AF (13). In case of plaques 4 mm thick but without
uperimposed mobile thrombus, antiplatelet agents are
ometimes prescribed without real evidence-based data.
nly one study in the literature (29) reported a beneficial
ffect of warfarin treatment over aspirin or ticlopidine on the
isk of embolic events in patients with plaques 4 mm
ithout mobile thrombus. That study, however, was small,nd the treatment was not randomized.
eThe results of the present study, while not sufficient to
uggest the use of systemic anticoagulation in this patient
roup, do indicate that stroke patients with large non-
obile aortic plaque should be tested for hypercoagula-
ility, and especially prothrombin fragment F 1.2 eleva-
ion, because of the increased risk of recurrent stroke and
eath that is associated with the combination of these 2
onditions. Specifically designed treatment trials are nec-
ssary to evaluate whether systemic anticoagulation may
ecrease the risk of subsequent events in this patient
opulation.
trengths and limitations. Our study is the first to assess
n a systematic fashion the association of proximal aortic
therosclerosis with hypercoagulability, and its impact on
he risk of recurrent ischemic stroke and death. The results
ay be of importance to provide context for planning
reatment trials to decrease vascular events in this patient
opulation. Although the study involved the performance of
he semi-invasive TEE, control subjects were community-
ased stroke-free volunteers rather than patient control
ubjects, which eliminated the possibility of referral bias and
llowed for a more accurate estimation of the differences
ith stroke patients.
The study has some limitations. Carotid duplex Doppler
as not performed in all subjects. Coagulation variables
ere not available or interpretable (because of pre-existing
nticoagulant treatment) in all subjects. Homocysteine lev-
ls were not measured. Also, 14% of stroke patients were
ost to follow-up; therefore, their influence on the results is
nknown. Finally, the relatively small sample size forced the
se of a composite end point of stroke and death for the
rospective component of the study.
onclusions
ur study shows that hypercoagulability is associated with
ortic plaque thickness in patients presenting with an acute
schemic stroke, and that the combination of large aortic
laques and hypercoagulability is associated with an in-
reased risk of recurrent stroke and death. Further studies
re necessary to explore the hypothesis that systemic anti-
oagulation may decrease the risk of events in this patient
opulation.
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